Related Experiment Video
Updated: May 23, 2026
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
Published on: July 18, 2016
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer
Agustin A Garcia1, Anne Yessaian, Huyen Pham
1Kenneth Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA. aagarcia@usc.edu
Unlabelled:
To evaluate the activity of gemcitabine and docetaxel in patients with recurrent ovarian cancer.
Methods:
Patients with platinum-resistant disease and prior treatment with paclitaxel received treatment with docetaxel on day 1 and gemcitabine on days 1 and 8, repeated every three weeks.
Results:
Twenty patients, with a platinum-free interval of three months, were enrolled. Overall response rate was 25%. Treatment was associated with significant myelosuppression.
Conclusions:
In chemotherapy-resistant patients, this regimen exhibited encouraging activity. Excessive myelosuppression led to early closure. This was prevented by administering docetaxel on day 8 (instead of day 1) and prophylactic use of G-CSF.
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers